JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

For the quarter ended December 2024, 10x Genomics (TXG) reported revenue of $165.02 million, down 10.3% over the same period last year. EPS came in at -$0.40, compared to -$0.41 in the year-ago ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

LyondellBasell's strong dividend track record and a 7% yield make it attractive for dividend investors, despite recent stock ...

Once bogged down by balance sheet stress and sluggish growth, many government-owned companies now stand on a firmer footing, ...

A hare can swivel, zigzag, and most importantly, make U-turns, the characteristics an investor needs when the bull market ...

In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most ...

The year was 2020, the month was February and Samsung had just kicked off yet another smartphone generation. The Galaxy S20 Ultra brought a lot of new features to the market, but crucially, Samsung’s ...